In contrast, gain-of-function mutations in SCN9A result in hyperexcitability of nociceptors and cause debilitating pain disorders such as primary erythromelalgia and paroxysmal extreme pain disorder8, 9. This evidence concerns the gene SCN9A and primary erythermalgia.